BGLA Stock Overview A healthcare company, provides probiotic products worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Add noteBioGaia AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for BioGaia Historical stock prices Current Share Price SEK 9.50 52 Week High SEK 11.63 52 Week Low SEK 8.36 Beta 0.58 1 Month Change 6.56% 3 Month Change -5.85% 1 Year Change 10.21% 3 Year Change -2.36% 5 Year Change 14.18% Change since IPO 991.11%
Recent News & Updates
BioGaia Launches A New Probiotic Supplement, BioGaia® Gastrus® PURE ACTION Dec 06
Third quarter 2024 earnings released: EPS: kr0.36 (vs kr1.01 in 3Q 2023) Oct 22
BioGaia AB (publ) to Report Q2, 2025 Results on Jul 18, 2025 Oct 22
Executive VP & CFO recently sold €996k worth of stock Sep 06
Second quarter 2024 earnings released: EPS: kr1.10 (vs kr0.80 in 2Q 2023) Jul 24
BioGaia AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025 Jul 23 See more updates
BioGaia Launches A New Probiotic Supplement, BioGaia® Gastrus® PURE ACTION Dec 06
Third quarter 2024 earnings released: EPS: kr0.36 (vs kr1.01 in 3Q 2023) Oct 22
BioGaia AB (publ) to Report Q2, 2025 Results on Jul 18, 2025 Oct 22
Executive VP & CFO recently sold €996k worth of stock Sep 06
Second quarter 2024 earnings released: EPS: kr1.10 (vs kr0.80 in 2Q 2023) Jul 24
BioGaia AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025 Jul 23
First quarter 2024 earnings released: EPS: kr1.21 (vs kr1.15 in 1Q 2023) May 07
Full year 2023 earnings released: EPS: kr3.62 (vs kr3.70 in FY 2022) Mar 26
Dividend of kr6.90 announced Feb 12
Full year 2023 earnings released: EPS: kr3.62 (vs kr3.70 in FY 2022) Feb 08 Biogaia AB (Publ) Proposes an Extra Dividend BioGaia AB (publ) to Report First Half, 2024 Results on Jul 07, 2024
Third quarter 2023 earnings released Oct 22 BioGaia AB (publ), Annual General Meeting, Apr 26, 2024
Biogaia AB (Publ) Provides Preliminarily Earnings Guidance for Third Quarter 2023 Oct 17
Biogaia AB (Publ) Appoints Theresa Agnew as CEO Sep 26
BioGaia AB (publ) Introduces BioGaia Prodentis KIDS in Sweden Sep 02
BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023 Aug 03
Second quarter 2023 earnings released Jul 21
BioGaia's probiotic Protectis increases SARS-CoV-2 antibody response in adults Jul 06
Less than half of directors are independent May 15
First quarter 2023 earnings released May 07 BioGaia AB (Publ) Approves Dividend for 2022
Upcoming dividend of kr2.90 per share at 2.8% yield May 01
Full year 2022 earnings released: EPS: kr3.70 (vs kr1.94 in FY 2021) Mar 31
Full year 2022 earnings released: EPS: kr3.70 (vs kr1.94 in FY 2021) Feb 05 BioGaia AB (publ) Proposes Ordinary Dividend
Third quarter 2022 earnings released Oct 22
Investor sentiment improved over the past week Oct 20
BioGaia AB (publ) Provides Earnings Guidance for the Third Quarter of 2022 Oct 17
Investor sentiment deteriorated over the past week Jul 29
Second quarter 2022 earnings released: EPS: kr0.78 (vs kr0.54 in 2Q 2021) Jul 25
Biogaia AB (publ) Provides Earnings Guidance for the Second Quarter of 2022 Jul 14
BioGaia AB (publ) Approves Extra Dividend May 08
First quarter 2022 earnings released May 07
Upcoming dividend of kr14.92 per share May 02
BioGaia AB (publ) Provides Earnings Guidance for the First Quarter of 2022 Apr 26 BioGaia AB (publ) Proposes Dividend, Payable on 13 May 2022
Full year 2021 earnings released: EPS: kr9.72 (vs kr10.07 in FY 2020) Mar 31 Biogaia AB (Publ) Proposes Ordinary Dividend
BioGaia's Probiotic Reduces Inflammation in Patients with Diverticulitis Feb 03
BioGaia AB (publ) Announces First Patient Enrolled in Phase II Clinical Study Evaluating BGP345A for the Treatment of Opioid Induced Constipation (OIC-1) Jan 26
Third quarter 2021 earnings released Oct 22
Second quarter 2021 earnings released: EPS kr2.71 (vs kr4.56 in 2Q 2020) Aug 13
BioGaia AB (publ) (OM:BIOG B) acquired remaining 8% stake in MetaboGen AB for SEK 11.4 million. Jul 03
Vice President of RA & Legal recently bought €10k worth of stock Jun 01
Biogaia AB (Publ) Approves Dividend May 07
First quarter 2021 earnings released May 06
Upcoming dividend of kr3.41 per share Apr 30
Full year 2020 earnings released: EPS kr10.07 Apr 04
New 90-day low: €43.00 Feb 20
CEO & President recently bought €9.8k worth of stock Feb 12
Full year 2020 earnings released: EPS kr10.07 (vs kr10.81 in FY 2019) Feb 06
Revenue beats expectations Feb 06
BioGaia AB (publ) Elects Niklas Ringby as New Board Member Nov 26
Market bids up stock over the past week Nov 05
BioGaia AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.144 billion. Oct 31
Third quarter earnings released Oct 24
Third-quarter earnings released: Revenue misses expectations Oct 24
Market pulls back on stock over the past week Oct 19
New 90-day low: €43.55 Oct 16
Market pulls back on stock over the past week Oct 16
Biogaia Announces L. reuteri Protectis Reduces Pain in Children with Functional Abdominal Pain Oct 05
New 90-day high - €57.50 Sep 03 BioGaia AB (publ) to Report First Half, 2021 Results on Aug 12, 2021
First half earnings released Aug 14
New 90-day high - €54.70 Aug 03 Shareholder Returns BGLA DE Biotechs DE Market 7D 1.5% -3.5% -2.0% 1Y 10.2% -14.7% 6.9%
See full shareholder returns
Return vs Market: BGLA exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is BGLA's price volatile compared to industry and market? BGLA volatility BGLA Average Weekly Movement 3.9% Biotechs Industry Average Movement 6.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: BGLA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BGLA's weekly volatility (4%) has been stable over the past year.
About the Company BioGaia AB (publ), a healthcare company, provides probiotic products worldwide. The company operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula.
Show more BioGaia AB (publ) Fundamentals Summary How do BioGaia's earnings and revenue compare to its market cap? BGLA fundamental statistics Market cap €970.17m Earnings (TTM ) €29.31m Revenue (TTM ) €117.98m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BGLA income statement (TTM ) Revenue SEK 1.36b Cost of Revenue SEK 358.07m Gross Profit SEK 997.60m Other Expenses SEK 660.78m Earnings SEK 336.82m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 12, 2025
Earnings per share (EPS) 3.33 Gross Margin 73.59% Net Profit Margin 24.85% Debt/Equity Ratio 0%
How did BGLA perform over the long term?
See historical performance and comparison Dividends
6.3% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 02:41 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources BioGaia AB (publ) is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Christopher Uhde ABG Sundal Collier Sponsored Kristofer Liljeberg-Svensson Carnegie Investment Bank AB Mattias Häggblom Danske Bank
Show 1 more analysts